Берестенникова Л. Н., Чумакова Г. А. Предикторы пароксизмальной формы тиреотоксической фибрилляции предсердий. Кардиоваскулярная терапия и профилактика. 2011;10(5):63-67.
1. Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the west Birmingham atrial fibrillation project. Br J Gen Pract 1997; 47: 285-9.
2. Krahn AD, Klein GJ, Kerr CR, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med1996; 156:
3. Fagerberg B, Lindstedt G, Stromblad SO, et al. Thyrotoxic atrial fibrillation: an underdiagnosed or overdiagnosed condition? Clin Chem 1990; 36:620-7.
4. Чумакова Г.А., Берестенникова Л.Н., Тимофеев А.В. и др. Распространенность дисфункций щитовидной железы среди пациентов с мерцательной аритмией. Мат Российского национального конгресса кардиологов “От диспансеризации к высоким технологиям”. Кардиоваск тер профил 2006; 5 (приложение): 418-9.
5. Fuster, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). JACC 2006; 48: 149-246.
6. Кушаковский М.С. Фибрилляция предсердий. СПб.: ИКФ “Фолиант” 1999; 176 с.
7. Кушаковский М.С. Аритмии сердца: Руководство для врачей. СПб: Гиппократ 1992; 544 с.
8. Nakazawa HK, Sakurai K, Hamada N, et al. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72: 903-6.
9. Nakazawa HK, Handa S, Nakamura Y, et al. High maintenance rate of sinus rhythm after cardioversion in post-thyrotoxic chronic atrial fibrillation. Int J Cardiol 1987; 16: 47-55.
10. Boelaert K, Franklyn JA. Thyroid hormone in health and disease. J Endocrinology 2005; 187: 1311-5.
11. Faizel O, Jayne AF, Roger LH, et al. Gammage Antithyroid Therapy: A Matched Case-Control Study Cardiovascular Manifestations of Hyperthyroidism Before and After. JACC 2007; 49: 71-81.
12. Nakazawa H, Lythall DA, Noh J, et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 2000; 21(4): 327-33.
13. American Association of Clinical Endocrinologist medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8: 457-66.
14. Клинические рекомендации. Эндокринология. Под ред. И.И. Дедова, Г.А. Мельниченко. Москва “ГЭОТАР-Медиа” 2007; 304 с.
15. McNamara RL, Brass LM, Drozda JP, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation 2004; 109(25): 3223-43.
16. Петри А., Сэбин К. Наглядная статистика в медицине. Пер. с англ. В.П.Леонова. Москва “ГЭОТАР-Медиа” 2003; 144 с.
17. Гланц С. Медико-биологическая статистика. Пер. с англ. Москва “Практика” 1998; 459 с.
18. Герасимов А.Н. Медицинская статистика: Учебное пособие. М.: ООО “Медицинское информационное агентство” 2007; 480 с.
19. Ruigómez A, Johansson S, Wallander M, et al. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovascular Disorders 2005; 5: 20.
